These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 39269404)

  • 1. CD19-chimeric antigen receptor-invariant natural killer T cells transactivate NK cells and reduce alloreactivity.
    Wesle A; Moraes Ribeiro E; Schairer R; Keppeler H; Korkmaz F; Radszuweit P; Bieber K; Lengerke C; Schneidawind D; Schneidawind C
    Cytotherapy; 2024 Aug; ():. PubMed ID: 39269404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity.
    Moraes Ribeiro E; Secker KA; Nitulescu AM; Schairer R; Keppeler H; Wesle A; Schmid H; Schmitt A; Neuber B; Chmiest D; Podavini S; Märklin M; Klimovich B; Schmitt M; Korkmaz F; Lengerke C; Schneidawind C; Schneidawind D
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38296597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
    Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
    Front Immunol; 2019; 10():3123. PubMed ID: 32117200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Culture-Expanded Human Invariant Natural Killer T Cells Suppress T-Cell Alloreactivity and Eradicate Leukemia.
    Schmid H; Schneidawind C; Jahnke S; Kettemann F; Secker KA; Duerr-Stoerzer S; Keppeler H; Kanz L; Savage PB; Schneidawind D
    Front Immunol; 2018; 9():1817. PubMed ID: 30127790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma.
    Poels R; Drent E; Lameris R; Katsarou A; Themeli M; van der Vliet HJ; de Gruijl TD; van de Donk NWCJ; Mutis T
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia.
    Yang N; Zhang C; Zhang Y; Fan Y; Zhang J; Lin X; Guo T; Gu Y; Wu J; Gao J; Zhao X; He Z
    J Transl Med; 2024 Mar; 22(1):274. PubMed ID: 38475814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human invariant natural killer T cells promote tolerance by preferential apoptosis induction of conventional dendritic cells.
    Schmid H; Ribeiro EM; Secker KA; Duerr-Stoerzer S; Keppeler H; Dong R; Munz T; Schulze-Osthoff K; Hailfinger S; Schneidawind C; Schneidawind D
    Haematologica; 2022 Feb; 107(2):427-436. PubMed ID: 33440919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL.
    Boeck CL; Amberger DC; Doraneh-Gard F; Sutanto W; Guenther T; Schmohl J; Schuster F; Salih H; Babor F; Borkhardt A; Schmetzer H
    J Immunother; 2017; 40(6):224-248. PubMed ID: 28557814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors.
    Oei VYS; Siernicka M; Graczyk-Jarzynka A; Hoel HJ; Yang W; Palacios D; Almåsbak H; Bajor M; Clement D; Brandt L; Önfelt B; Goodridge J; Winiarska M; Zagozdzon R; Olweus J; Kyte JA; Malmberg KJ
    Cancer Immunol Res; 2018 Apr; 6(4):467-480. PubMed ID: 29459477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
    Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
    Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein.
    Das R; Guan P; Wiener SJ; Patel NP; Gohl TG; Evans E; Zauderer M; Nichols KE
    Blood Adv; 2019 Mar; 3(5):813-824. PubMed ID: 30858151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.
    Ghosh A; Smith M; James SE; Davila ML; Velardi E; Argyropoulos KV; Gunset G; Perna F; Kreines FM; Levy ER; Lieberman S; Jay HV; Tuckett AZ; Zakrzewski JL; Tan L; Young LF; Takvorian K; Dudakov JA; Jenq RR; Hanash AM; Motta AC; Murphy GF; Liu C; Schietinger A; Sadelain M; van den Brink MR
    Nat Med; 2017 Feb; 23(2):242-249. PubMed ID: 28067900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering.
    Oberschmidt O; Morgan M; Huppert V; Kessler J; Gardlowski T; Matthies N; Aleksandrova K; Arseniev L; Schambach A; Koehl U; Kloess S
    Hum Gene Ther Methods; 2019 Jun; 30(3):102-120. PubMed ID: 30997855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia.
    Quintarelli C; Sivori S; Caruso S; Carlomagno S; Falco M; Boffa I; Orlando D; Guercio M; Abbaszadeh Z; Sinibaldi M; Di Cecca S; Camera A; Cembrola B; Pitisci A; Andreani M; Vinti L; Gattari S; Del Bufalo F; Algeri M; Li Pira G; Moseley A; De Angelis B; Moretta L; Locatelli F
    Leukemia; 2020 Apr; 34(4):1102-1115. PubMed ID: 31745215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies.
    Chen X; Tan B; Xing H; Zhao X; Ping Y; Zhang Z; Huang J; Shi X; Zhang N; Lin B; Cao W; Li X; Zhang X; Li L; Jiang Z; Zhang M; Li W; Liu M; Du B; Zhang Y
    Cancer Immunol Immunother; 2024 Jan; 73(1):13. PubMed ID: 38231412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
    Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
    Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
    Liu E; Marin D; Banerjee P; Macapinlac HA; Thompson P; Basar R; Nassif Kerbauy L; Overman B; Thall P; Kaplan M; Nandivada V; Kaur I; Nunez Cortes A; Cao K; Daher M; Hosing C; Cohen EN; Kebriaei P; Mehta R; Neelapu S; Nieto Y; Wang M; Wierda W; Keating M; Champlin R; Shpall EJ; Rezvani K
    N Engl J Med; 2020 Feb; 382(6):545-553. PubMed ID: 32023374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies.
    Soldierer M; Bister A; Haist C; Thivakaran A; Cengiz SC; Sendker S; Bartels N; Thomitzek A; Smorra D; Hejazi M; Uhrberg M; Scheckenbach K; Monzel C; Wiek C; Reinhardt D; Niktoreh N; Hanenberg H
    Front Immunol; 2022; 13():847008. PubMed ID: 35464442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19
    Liu Q; Xu Y; Mou J; Tang K; Fu X; Li Y; Xing Y; Rao Q; Xing H; Tian Z; Wang M; Wang J
    Cytotherapy; 2020 Oct; 22(10):552-562. PubMed ID: 32747298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.